Governments and companies from different countries are competing to introduce the world's first licensed vaccine, but experts say that in order to better serve the people, it is necessary to wait until at least 30 to 50. Percentage effective vaccines are not developed.
The United Kingdom announced last week that it would expedite the approval of any vaccine by the end of this year, while US President Donald Trump wants to announce a vaccine before the scheduled presidential election in November.
The vaccine is needed to control the corona virus epidemic, but Sir Richard Peto, a professor at Oxford University and an adviser to the World Health Organization, says the first vaccine will be purchased and used worldwide, even if it is not very effective.
He said that if the vaccine could protect only a small part of the population, it would be considered a standard for other vaccines, while the possibility of adopting more defective vaccines would increase later.
"I think everyone is acting hastily, which is also a kind of haste of national pride and earning, that one vaccine should be registered first and when that happens, it will be more difficult to analyze other vaccines," he said. "We need a vaccine and we need it very soon, but we will also need solid evidence for its effectiveness."
Vaccine trials are taking place in a number of countries, including South Africa and Brazil, which are more affected than Corona, with trials by other countries, the results of which will give a quick idea of the effectiveness of the vaccine.
The Oxford University vaccine is currently leading the race, but four vaccines have also entered the final stages of human testing in China.
The British Department of Health said on August 28 that it was taking "emergency measures" to ensure that a single vaccine was licensed in the UK this year on adequate evidence of safety and efficacy.
The UK will have to wait until December 31 for approval from the European Medicines Agency, but after Bridget next year, the UK will be able to license its own vaccines and medicines.
According to the British government, the Joint British Committee on Vaccines will be responsible for advancing the licensing process for a vaccine headed by Professor Andrew Pollard, director of the Oxford Vaccine Group.
Sir Richard Peto is a member of the World Health Organization's Integrated Vaccines Trial Expert Group, a group of leading scientists from around the world, whose purpose is to advise the World Health Organization on various vaccines.
The group said last week in the medical journal The Lancet that a low-quality vaccine could make an epidemic worse than no vaccine, because its use would make people think they were no longer at risk and socially isolated. The implementation of the measures will be stopped.
The group said a less effective vaccine would exacerbate the epidemic of Code 19 because the administration felt that the risk had now been significantly reduced or that people undergoing the vaccine would have a false sense of safety. As a result, they will not take precautions.
The group urged all regulators to follow the World Health Organization's guidelines, which say vaccines less than 30 percent effective should not be approved under any circumstances, but at least 50 percent effective. ۔
The US Food and Drug Administration says it will follow the advice, but some observers believe the agency could issue a license for a vaccine under political pressure.
The group of global scientists said that solidarity with various vaccines is the best way to move forward.
"By comparing individual trials of different vaccines, a global multi-vaccine trial that is shared with a control group will yield faster and more reliable results," he said.
